Michael S Schechter

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis
    Michael S Schechter
    Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Pediatr 155:634-9.e1-4. 2009
  2. ncbi request reprint Airway clearance applications in infants and children
    Michael S Schechter
    Department of Pediatrics, Emory University School of Medicine, Emory Children s Center, 2015 Uppergate Drive, Suite 326, Atlanta, GA 30322 0001
    Respir Care 52:1382-90; discussion 1390-1. 2007
  3. doi request reprint Nongenetic influences on cystic fibrosis outcomes
    Michael S Schechter
    Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, 1547 Clifton Road, Atlanta, GA 30322, USA
    Curr Opin Pulm Med 17:448-54. 2011
  4. ncbi request reprint Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis
    Michael S Schechter
    Emory University School of Medicine and Children s Healthcare of Atlanta, Atlanta, GA, USA
    J Pediatr 159:819-824.e1. 2011
  5. doi request reprint Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms
    Warren E Regelmann
    Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Pediatr Pulmonol 48:649-57. 2013
  6. ncbi request reprint Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function
    Clement L Ren
    Department of Pediatrics, University of Rochester, Rochester, New York 14642, USA
    Pediatr Pulmonol 42:513-8. 2007
  7. doi request reprint Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis
    Clement L Ren
    Department of Pediatrics, University of Rochester, Rochester, NY, USA
    J Pediatr 153:746-51. 2008
  8. ncbi request reprint Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function
    Raj Padman
    Department of Pediatrics, Alfred I duPont Hospital for Children, Nemours Children s Clinic, Wilmington, DE 19899, USA
    Pediatrics 119:e531-7. 2007
  9. doi request reprint Genetic and non-genetic determinants of outcomes in cystic fibrosis
    Linda L Wolfenden
    Emory Cystic Fibrosis Center, Emory University, Atlanta, Georgia, USA
    Paediatr Respir Rev 10:32-6. 2009
  10. doi request reprint Healthcare expenditures for privately insured people with cystic fibrosis
    Lijing Ouyang
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Pediatr Pulmonol 44:989-96. 2009

Detail Information

Publications20

  1. ncbi request reprint Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis
    Michael S Schechter
    Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Emory University School of Medicine, Atlanta, GA 30322, USA
    J Pediatr 155:634-9.e1-4. 2009
    ....
  2. ncbi request reprint Airway clearance applications in infants and children
    Michael S Schechter
    Department of Pediatrics, Emory University School of Medicine, Emory Children s Center, 2015 Uppergate Drive, Suite 326, Atlanta, GA 30322 0001
    Respir Care 52:1382-90; discussion 1390-1. 2007
    ..All in all, however, given that these conclusions are based on very little data, future well-performed clinical trials might change the weight of evidence to contradict these current conclusions...
  3. doi request reprint Nongenetic influences on cystic fibrosis outcomes
    Michael S Schechter
    Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Department of Pediatrics, Emory University School of Medicine, 1547 Clifton Road, Atlanta, GA 30322, USA
    Curr Opin Pulm Med 17:448-54. 2011
    ....
  4. ncbi request reprint Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis
    Michael S Schechter
    Emory University School of Medicine and Children s Healthcare of Atlanta, Atlanta, GA, USA
    J Pediatr 159:819-824.e1. 2011
    ..To determine whether socioeconomic status (SES) influences the likelihood of antibiotic treatment of pulmonary exacerbations in patients with cystic fibrosis (CF)...
  5. doi request reprint Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms
    Warren E Regelmann
    Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Pediatr Pulmonol 48:649-57. 2013
    ....
  6. ncbi request reprint Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function
    Clement L Ren
    Department of Pediatrics, University of Rochester, Rochester, New York 14642, USA
    Pediatr Pulmonol 42:513-8. 2007
    ..Similar results were seen in patients >or=18 years old. The results of our study highlight the growing clinical impact of MRSA infections in CF patients...
  7. doi request reprint Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis
    Clement L Ren
    Department of Pediatrics, University of Rochester, Rochester, NY, USA
    J Pediatr 153:746-51. 2008
    ....
  8. ncbi request reprint Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function
    Raj Padman
    Department of Pediatrics, Alfred I duPont Hospital for Children, Nemours Children s Clinic, Wilmington, DE 19899, USA
    Pediatrics 119:e531-7. 2007
    ..The aim of this study was to assess whether patterns of care for infants at cystic fibrosis sites with superior average lung function in 6- to 12-year-old children showed any differences from those at the lowest outcome sites...
  9. doi request reprint Genetic and non-genetic determinants of outcomes in cystic fibrosis
    Linda L Wolfenden
    Emory Cystic Fibrosis Center, Emory University, Atlanta, Georgia, USA
    Paediatr Respir Rev 10:32-6. 2009
    ..Many factors contribute to improvements in disease severity and outcome. This paper reviews the current evidence of three groups of important factors: genetic, environmental and healthcare related...
  10. doi request reprint Healthcare expenditures for privately insured people with cystic fibrosis
    Lijing Ouyang
    National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Pediatr Pulmonol 44:989-96. 2009
    ..People with CF will incur high medical expenditures throughout their lifespan. These findings will assist in the development of economic evaluations of future CF screening and management initiatives...
  11. doi request reprint Benchmarking to improve the quality of cystic fibrosis care
    Michael S Schechter
    Emory University School of Medicine, Children s Healthcare of Atlanta, Atlanta, Georgia 30322, USA
    Curr Opin Pulm Med 18:596-601. 2012
    ..This review summarizes reports of how benchmarking has been operationalized in attempts to improve CF care...
  12. ncbi request reprint Non-genetic influences on CF lung disease: the role of sociodemographic characteristics, environmental exposures and healthcare interventions
    Michael S Schechter
    Department of Pediatrics, Rhode Island Hospital, 593 Eddy Street, Suite POB 440, Providence, RI 02903, USA
    Pediatr Pulmonol Suppl 26:82-5. 2004
  13. doi request reprint Testing the feasibility of a National Spina Bifida Patient Registry
    Judy K Thibadeau
    Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA 30333, USA
    Birth Defects Res A Clin Mol Teratol 97:36-41. 2013
    ....
  14. doi request reprint Improving the quality of care for patients with cystic fibrosis
    Michael S Schechter
    Department of Pediatrics, Division of Pulmonary, Allergy Immunology, Cystic Fibrosis and Sleep, Emory University School of Medicine, Children s Healthcare of Atlanta, Atlanta, Georgia 30322, USA
    Curr Opin Pediatr 22:296-301. 2010
    ..This article describes the factors that have contributed to the recent acceleration in this improvement and the important role of the Cystic Fibrosis Foundation...
  15. ncbi request reprint Improving subspecialty healthcare: lessons from cystic fibrosis
    Michael S Schechter
    Department of Pediatrics, Brown Medical School, Rhode Island Hospital Hasbro Children s Hospital, Providence, Rhode Island 02903, USA
    J Pediatr 147:295-301. 2005
  16. ncbi request reprint Sweat-testing in preterm and full-term infants less than 6 weeks of age
    Warren Eng
    Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7145, USA
    Pediatr Pulmonol 40:64-7. 2005
    ..In conclusion, sweat collection can be reliably performed in infants > or = 36 weeks postmenstrual age, > 2,000 g, and > 3 days postnatal age. Maturational factors have a mild impact on sweat chloride concentration...
  17. ncbi request reprint Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium
    Pierre M Barker
    Department of Pediatrics, University of North Carolina at Chapel Hill, 200 Mason Farm Road, Chapel Hill, NC 27599 7220, USA
    Am J Respir Crit Care Med 171:868-71. 2005
    ..We conclude that the apparent beneficial effects of macrolides on pulmonary outcome in CF are not mediated by their modulation of ion transport...
  18. pmc Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
    J P Clancy
    Department of Pediatrics, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Thorax 67:12-8. 2012
    ..VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro...
  19. ncbi request reprint Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy
    Ingrid M Hoffmann
    Department of Pediatrics, Wake Forest University School of Medicine Baptist Medical Center, Winston Salem, North Carolina 27157 1081, USA
    Pediatr Pulmonol 34:375-7. 2002
    ..Measurable tobramycin levels due to inhalational therapy with conventional dosing in the reported patient indicate that the drug can be systemically absorbed, and renal tubular toxicity may occur...
  20. ncbi request reprint Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis
    Kenneth N Olivier
    The Cystic Fibrosis Pulmonary Research and Treatment Center, The Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Am J Respir Crit Care Med 167:828-34. 2003
    ..Older age was the most significant predictor for isolation of NTM. The clinical significance of NTM in CF is incompletely defined, but patients with these organisms should be monitored with repeat cultures...